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Abstract
Evolutionary trade-offs occur when selection on one trait has detrimental effects on other traits. In pathogenic microbes, it has
been hypothesized that antibiotic resistance trades off with fitness in the absence of antibiotic. Although studies of single
resistance mutations support this hypothesis, it is unclear whether trade-offs are maintained over time, due to compensatory
evolution and broader effects of genetic background. Here, we leverage natural variation in 39 extraintestinal clinical isolates of
Escherichia coli to assess trade-offs between growth rates and resistance to fluoroquinolone and cephalosporin antibiotics.
Whole-genome sequencing identifies a broad range of clinically relevant resistance determinants in these strains. We find
evidence for a negative correlation between growth rate and antibiotic resistance, consistent with a persistent trade-off between
resistance and growth. However, this relationship is sometimes weak and depends on the environment in which growth rates are
measured. Using in vitro selection experiments, we find that compensatory evolution in one environment does not guarantee
compensation in other environments. Thus, even in the face of compensatory evolution and other genetic background effects,
resistance may be broadly costly, supporting the use of drug restriction protocols to limit the spread of resistance. Furthermore,
our study demonstrates the power of using natural variation to study evolutionary trade-offs in microbes.
Key words: antibiotic resistance, trade-off, whole-genome sequencing, compensatory evolution, epistasis.
Introduction
Trade-offs occur when an improvement in one trait is accom-
panied by deterioration in another. Evolutionary biologists
have had a long-standing interest in trade-offs, dating back
at least to Darwin, who recognized that directional selection
on a given trait would often have unforeseen, and frequently
detrimental, effects on other traits (Darwin 1859; Agrawal
et al. 2010). The negative correlations that result from
trade-offs are thought to be important drivers of both intra-
and interspecific diversity (Schluter 1996; Clark et al. 2007;
Ferenci 2016), and may limit the extent and pace of adapta-
tion (Futuyma and Moreno 1988; Agrawal and Stinchcombe
2009).
Fitness costs associated with antimicrobial resistance (AMR)
constitute a trade-off of particular importance to human
health. It is often assumed that AMR is accompanied by re-
duced fitness in the absence of antibiotic—AMR pathogens
may suffer from reduced competitive ability (Melnyk et al.
2015; Vogwill and MacLean 2015), growth rates (Bagel et al.
1999), and/or virulence (Alonso et al. 2004; Olivares et al.
2012). This assumption underlies public health efforts to re-
duce the prevalence of resistance by restriction of antibiotic
use (Enne 2010): costly resistance mutations should decrease
in frequency in the absence of drug. Consistent with this as-
sumption, laboratory studies on the fitness effects of individual
AMR elements (either chromosomal mutations or mobile ele-
ments) typically findcosts, althoughsome resistancemutations
appear to be cost-free (Andersson 2006; Melnyk et al. 2014;
Hughes and Andersson 2015; Vogwill and MacLean 2015). In
extreme cases, such as the antifungal drug amphotericin B,
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resistance is so costly as to prevent emergence of clinically rel-
evant resistance (Vincent et al. 2013).
Nonetheless, while individual resistance elements may im-
pose reduced fitness, these costs can be mitigated by genetic
background (reviewed in Wong 2017). In some cases, segre-
gating polymorphism can mitigate the costs of resistance. For
example, fitness of the quinolone resistant gyrA C257T mu-
tation in Campylobacter jejuni can vary drastically depending
on background. On one background, this mutation is costly
and is outcompeted by susceptible genotypes in a chicken
model of infection. On an alternative genetic background,
however, resistance is cost-free, and in fact the resistant mu-
tant outcompetes susceptible strains (Luo et al. 2005).
Similarly, background-specific costs have been documented
for other resistance mutations and for plasmid-mediated re-
sistance (Bjo¨rkholm et al. 2001; Humphrey et al. 2012).
Even when a mutation is initially costly on a given back-
ground, fitness can be readily recovered in the lab by serially
passaging resistant populations in drug-free media for dozens
to hundreds of generations (Bouma and Lenski 1988;
Bjorkman et al. 2000; Dionisio et al. 2005; Kugelberg et al.
2005). Importantly, at least some degree of resistance is typ-
ically maintained following serial passage, indicating that fit-
ness recovery is not due to simple reversion of the original
resistance mutation. Thus, mutations elsewhere in the
genome—referred to as “compensatory mutations”—can
mitigate the costs of resistance, and may be either
presegregating, or arise following the acquisition of resistance.
Given considerations of genetic background and compen-
satory evolution, it is still unclear whether AMR is accompa-
nied by costs “in the wild”—that is, among microbes found in
clinical, environmental, and/or agricultural settings. Although
compensation is easily attainable in the lab, data are sparse
concerning its importance in clinical settings: there are strong
data to support compensation for costs of rifampicin resis-
tance in Mycobacterium tuberculosis (Brandis et al. 2012;
Cohen et al. 2015; Coscolla et al. 2015), but not in other
systems. The question thus remains as to whether AMR trades
off with other fitness components in natural populations.
In studying trade-offs associated with resistance, microbi-
ologists have focused on the costs imposed by specific AMR
mutations. An alternative approach has been widely used in
animal and plant systems, and to a lesser extent in microbes
(reviewed in Stearns 1989; Agrawal and Stinchcombe 2009;
Ferenci 2016). The underlying premise is straightforward. Two
traits, such as offspring number and offspring size, may both
be under directional selection for more extreme values. If
there is a trade-off between these traits—perhaps because
resources are limiting—then we expect to observe a negative
correlation between them; offspring may be large or numer-
ous, but they cannot be both. Trade-offs are widespread in
natural populations, for example, between survival and repro-
duction (Clutton-Brock et al. 1983), between insect perfor-
mance on alternate host plants (Via and Hawthorne 2002),
and between senescence and rapid reproduction (Partridge
1987).
Negative trait correlations have been used to infer trade-
offs in a number of cases in microbes (Ferenci 2016). Most
relevantly, Phan and Ferenci (2013) found a negative correla-
tion between competitive fitness and resistance to two anti-
microbials (the antibiotic chloramphenicol and the detergent
SDS) among natural isolates of Escherichia coli derived from a
range of animal and primarily healthy human sources. They
were able to attribute this tradeoff, at least in part, to natural
variation in membrane permeability, which governs the entry
of both the antimicrobials and nutrients into the cell.
However, to our knowledge, there has not been a natural-
variation based study of the trade-offs of clinically relevant
AMR in microbes.
Here, we address trade-offs between AMR and growth
rates in clinical isolates of E. coli. In keeping with the assump-
tions of trade-off theory, we expect both resistance and
growth rates to be under directional selection, at least some
of the time: resistance should be selected for when antibiotics
are present, and growth rates should be selected for during
infection and under nutrient-rich environmental conditions.
As such, if there is a trade-off between resistance and growth,
we predict a negative correlation between these two traits.
We go on to investigate mechanisms underlying the inferred
trade-offs, and suggest that mitigation of the costs of resis-
tance may be limited by the environmental specificity of com-
pensatory mutations.
Materials and Methods
Strains and Growth Conditions
Thirty-nine extraintestinal pathogenic E. coli (ExPEC; Dale and
Woodford 2015) isolates, collected as part of the CANWARD
survey of antibiotic resistant pathogens in Canada (Lagace-
Wiens et al. 2013; Zhanel et al. 2013), were obtained from
the Zhanel laboratory at the University of Manitoba. These
isolates were collected from patients at hospitals across
Canada, from a variety of nongastrointestinal infection types,
including urinary tract, blood, wound, and respiratory infec-
tions (supplementary table S1, Supplementary Material on-
line). These isolates represent a wide range of quinolone
and b-lactam sensitivities. Enterohemorrhagic (EHEC) strains
of intestinal origin were excluded since antibiotic use is contra-
indicated for these infections due to an increased risk of
haemolytic-uremic syndrome (Goldwater and Bettelheim
2012). Additional experiments were carried out using the E.
coli laboratory strain K-12 (MG1655), as well as two CipR
derivatives of MG1655, one carrying a gyrA D87G mutation,
and the other carrying a marR R94C mutation (Wong and
Seguin 2015).
Cultures were grown in lysogeny broth (LB; 10 g/l tryptone,
5 g/l yeast extract, 10 g/l NaCl), tryptic soy broth (TSB;
17 g/l tryptone, 3 g/l phytone, 5 g/l NaCl, 2.5 g/l K2HPO4,
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2.5 g/l glucose), or M9 minimal mediaþ glucose (M9; 1 g/l
NH4Cl, 3 g/l KH2PO4, 0.5 g/l NaCl, 6.8 g/l Na2HPO4; 15 mg/l
CaCl2 15 mg/l, 0.5 g/l MgSO4; 0.8% dextrose) overnight at
37C with shaking at 150 rpm, unless otherwise indicated.
Phenotypic Assays
Antibiotic resistance was measured using minimum inhibitory
concentration (MIC) assays (Andrews 2001). MICs were mea-
sured for four drugs: the quinolone ciprofloxacin, and the b-
lactams ampicillin (a penicillin), meropenem (a carbapenem),
and ceftazidime (a third generation cephalosporin). The use of
these three b-lactams enabled us to distinguish between dif-
ferent types of b-lactamase, since only ESBLs will display high
level resistance to ceftazidime, and only carbapenemases will
confer resistance to meropenem. Overnight cultures of each
strain were inoculated at a 1:100 dilution into 150ll LB, with
a 2-fold dilution of ciprofloxacin, ampicillin, ceftazidime, and
meropenem ranging from 32 000 ng/ll to 7.8 ng/ll,
1,024lg/ml to 0.25lg/ml, 128lg/ml to 0.25lg/ml, and
16lg/ml to 0.25lg/ml, respectively. Following 18 h of
growth at 30C with shaking at 150 rpm, optical density
(OD) was measured at 600 nm. The MIC was defined as the
concentration of antibiotic that visibly inhibited growth after
overnight culture.
Growth curves were measured in LB, TSB, and
M9þ glucose. Growth curves were collected from shaken
150ll cultures in 96-well plates at 37C, inoculated at a
1:100 dilution from over-night cultures. OD600 was measured
every 37 min for 24 h, and lag phase, maximum growth rate,
and density at stationary phase were estimated using
GrowthCurves (Hall et al. 2014) with two replicates for
each strain. We validated the use of growth curves to assess
population density for a subset of strains (supplementary fig.
S1, Supplementary Material online).
Whole-Genome Sequencing and Assembly
For each clinical isolate, a single colony was picked and grown
overnight in drug-free LB. Genomic DNA was extracted using
the One-4-All Genomic DNA Mini-prep Kit (Bio Basic) as de-
scribed in the manufacturer’s manual. Following DNA purifi-
cation, DNA quantification was performed using the Quant-iT
PicoGreen dsDNA Assay Kit (Invitrogen). Library construction
was carried out using the Nextera XT kit (Illumina). Libraries
were then quantified by qPCR (KAPA Biosystems).
Sequencing was carried out on the Illumina Miseq platform
using paired-end, 300-bp reads. All raw sequence data have
been uploaded to the NCBI short read archive (accession
numbers SRP132562).
Quality control on the raw sequence files was performed
using Trimmomatic-0.32 (Bolger et al. 2014). Fifteen bases
from the beginning, and one base from the end, were re-
moved from each read. In addition, reads were trimmed using
a sliding window, with each read clipped once average
base-call quality score dropped <20 in a 4-bp window.
Reads of fewer than 36 bp were also removed. Effects of
quality control were visualized by FastQC, assuring that high
quality data were used in further analyses (https://www.bio-
informatics.babraham.ac.uk/projects/fastqc/).
Reference based alignment was carried out to identify sin-
gle nucleotide polymorphisms (SNPs) in known resistance
genes. E. coli K-12 (MG1655; NC_00913) was used as the
reference genome. Assembly was performed using Bowtie2
v2.1.0 (Langmead et al. 2009), and SNPs were called using
Samtools (Li et al. 2009). The quality of the alignment was
assessed using Qualimap, version 2.0.1 (Garcia-Alcalde et al.
2012) and custom Perl scripts were used to filter SNPs (cov-
erage >15, Phred-scale quality >20 and a frequency of 80%
or higher).
De novo assemblies were constructed for all strains in order
to conserve information regarding accessory genomes, which
can be lost in a reference-based approach. The accessory
genome contains strain-specific genes that are involved in
processes like niche adaptation, specialization, and host-
switching (Dobrindt and Hacker 2001; Didelot et al. 2009).
VelvetOptimiser-2.2.5 was used to determine the optimal
k-mer length for the data and de novo assemblies were con-
structed using Velvet-1.2.10 (Zerbino and Birney 2008).
Contigs shorter than 200 bp were removed to improve the
quality of the assemblies. QUAST-3.1 was used to assess the
assemblies (Gurevich et al. 2013). Genomes were annotated
using the toolkit provided by Rapid Annotation using
Subsytem Technology (RAST) for batch submission (Brettin
et al. 2015).
Multisequence Alignment, Phylogenetic Inference, and
Phylogenetic Correlations
Whole-genome alignment was carried out using our de novo
assemblies of 39 clinical isolates, along with the genomes of
E. coli K-12 (MG1655), E. coli 0157, and the outgroup species
E. fergusonii (GenBank accession numbers NC_00913,
BA000007.2, and NC_011740.1, respectively).
ProgressiveMauve-2.4.0 was used to align the genomes
with iterative refinement using default settings (Darling
et al. 2010). ProgressiveMauve is a multiple alignment tool
that identifies locally collinear blocks (LCBs), each being a ho-
mologous region of sequence shared between genomes.
LCBs shared among all 42 genomes were classified as the
“core genome,” whereas others were considered to be part
of the “accessory genome.” A core genome phylogeny was
constructed using Bayesian phylogenetic inference as imple-
mented by BEAST (Drummond et al. 2012), using a general
time-reversible model with gamma correction (GTRGAMMA
model). The Markov chain Monte Carlo (MCMC) chain was
run for 20 million generations with sampling every 1,000
generations. The phylogenetic tree was visualized using
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FigTree version 1.4.2 (http://tree.bio.ed.ac.uk/software/
figtree/).
BayesTrait 2.0 (Pagel et al. 2004) was used to infer
phylogenetically informed correlations between phenotypic
traits. The covarion model for trait evolution was enabled,
and we used a variant of the continuous-time Markov model
that allows for traits to vary their rates of evolution within and
between branches. The MCMC chain consisted of 101,000
iterations, of which the first 10,000 were discarded as burn-
in. The chain was sampled every 1,000 iterations, and 95%
credible intervals for parameter estimates were calculated as
the 2.5% and 97.5% quantiles. Inference of correlated evo-
lution was carried out by running two chains, one allowing
correlated evolution, and one disallowing correlated evolu-
tion. These two chains were compared using Bayes factors
(BF), which indicate the degree of support for the correlated
evolution model over the independent evolution model.
Heuristically, BF< 2 indicates weak or no support for a corre-
lation, BF of 2–6 indicate positive support, and BF of 6–10
indicate strong support (Kass and Raftery 1995).
Serotyping and Resistance Gene Prediction
Serotype prediction of the strains was carried out using
SerotypeFinder 1.1, a publicly available web tool at the
Center for Genomic Epidemiology (CGE) (Joensen et al.
2015). E. coli serotypes are defined based on the O and H
antigens. The O antigen contains repeats of an oligosaccha-
ride unit, and is part of the lipopolysaccharides present in the
outer membrane of Gram-negative bacteria (Wang et al.
1998). The H antigen is the central, variable region of the
flagellin protein of E. coli (Wang et al. 2003). Serotypes
were characterized based on a threshold of 85% identity
and minimum length of 60%.
ResFinder 2.1, also available at CGE, was used to identify
genes associated with antibiotic resistance. Genes were iden-
tified based on a threshold of 98% identity and minimum
length of 60% (Zankari et al. 2012). Mutations in chromo-
somal genes contributing to quinolone resistance (e.g., gyrA,
gyrB, parC, and marR) were identified by manual inspection.
Here, a custom Perl script was used to extract SNP calls from
reference-based alignments, and multiple-alignments for
each gene of interest were visualized using MEGA 6
(Tamura et al. 2013).
Laboratory Selection and Competitive Fitness Assays
Compensatory evolution experiments were carried out using
12 replicate populations of the CipR mutants gyrA D87G and
marR R94C. Populations were grown in 200ll of drug-free
liquid LB in a 96-well plate, shaking at 150 rpm at 30C. Every
24 h, 2ll of culture were transferred to fresh media for a
1:100 dilution. Selection was carried out for 15 days, for a
total of 100 generations of selection.
Single colony isolates from each evolved population, as
well as of the initial genotypes, were then subjected to com-
petitive fitness assays against a Lac derivative of MG1655
(NCM520). Three to six replicate fitness assays were per-
formed in each of LB, TSB, and M9 minimal mediaþ glucose.
Equal volumes of NCM520 and a given mutant genotype
were inoculated at a 1:100 dilution in 200ll LB, followed
by an overnight incubation at 30C in LB with shaking.
Relative frequencies of each genotype were estimated from
counts of blue (CipR) and white (CipS) colonies on LB
agarþ IPTGþX-gal at the beginning and end of the compe-
tition experiment. Relative fitness (in units of per generation)
was then calculated for each replicate using the following
equation:
w ¼ 1 þ ðln ½whitefinal=whiteinitial
 ½ln ½bluefinal=blueinitialÞ=# generations:
Here, given the 1:100 dilution, the competition was
allowed to proceed for 6.6 generations.
Results and Discussion
Variation in Phenotypic Traits
We investigated tradeoffs associated with drug resistance us-
ing a collection of 39 clinical isolates of Escherichia coli. These
ExPEC strains were obtained from a variety of nongastrointes-
tinal infections, and fall into four broad classes of drug resis-
tance: drug susceptible; extended-spectrum b-lactamase
positive (ESBL, capable of degrading cephalosporins such as
ceftazidime); ciprofloxacin-resistant (CipR) but ESBL-negative;
and multidrug resistant CipR, ESBL-positive.
We measured a range of phenotypic characteristics in all
39 strains, and found substantial variation for most traits
tested (fig. 1). Resistance to ciprofloxacin and to ceftazidime
varied by 1,024- and 512-fold, respectively, as expected given
that we intentionally sampled both susceptible and resistant
isolates (fig. 1A and B). According to CLSI clinical resistance
breakpoints (Clinical and Laboratory Standards Institute
2018), 13 isolates show only ciprofloxacin resistance
(MIC4lg/ml), 6 show only ceftazidime resistance
(MIC16lg/ml), and 11 show resistance to both drugs.
Resistance to meropenem showed much less variation
(fig. 1C), indicating that none of these strains is carbapene-
mase positive (CLSI breakpoint: 4lg/ml). Variation was also
evident for growth rate (a proxy for fitness) in three different
laboratory media—lysogeny broth (LB), tryptic soy broth
(TSB), and M9 minimal mediumþ glucose (fig. 1D–F).
Trade-Offs of Drug Resistance
Trade-off theory predicts negative correlations between traits
under directional selection, if both traits cannot be simulta-
neously optimized. Consistent with this prediction, we find
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evidence for tradeoffs between drug resistance and growth
rates in this set of clinical isolates. We find a strong negative
correlation between level of ceftazidime resistance and
growth rate in TSB (P¼ 0.005, fig. 2A), and negative but
nonsignificant relationships between other drug resistance
and growth rate pairs (fig. 2B–F). In order to provide a more
robust statistical analysis, we combined data from all three
environments using a linear regression model, with environ-
ment and drug as main effects. We find negative relationships
between drug resistance and growth rates, although the ef-
fect of ceftazidime resistance is nonsignificant (table 1). An
observed reduction in growth rates in minimal medium is
expected, since this defined medium represents a more
nutrient-limited environment. Notably, interaction effects be-
tween drug resistance and growth environment were non-
significant in all cases. This suggests that tradeoffs are broadly
consistent across growth conditions, although they may be
weak.
In phylogenetically structured data, correlations between
traits may be spuriously strengthened or weakened by shared
history (Felsenstein 1985; Velicer et al. 1999), since closely
related species are expected to exhibit similarity solely due
to ancestry. In order to correct for any potential bias due to
underlying phylogeny, we carried out phylogenetically in-
formed, Bayesian correlational analyses. Here, trait evolution
is explicitly modeled on a phylogenetic tree, so that the ap-
propriate null expectations can be generated. Following
whole-genome sequencing, a core-genome phylogeny was
constructed under a general-time reversible model, and was
used to infer phylogenetic-controlled correlations using
BayesTraits (Pagel et al. 2004; see Materials and Methods
for more details). We find strong evidence for trade-offs as-
sociated with antibiotic resistance (fig. 3). Resistances to both
ceftazidime and ciprofloxacin are negatively associated
with growth rate in TSB (fig. 3A; Bayes Factors of 6.78
and 9.18, respectively) and in LB (fig. 3B, BF¼ 4.17 and
3.40), although not in minimal medium (fig. 3C, BF¼ 0.05
and 0.10).
It is currently unclear whether phylogenetic or nonphylo-
genetic methods are more appropriate for measuring trait
correlations in bacteria. Recombination is common in many
bacterial species, including E. coli, such that different phylog-
enies underlie different regions of the genome. The presence
of recombination is known to confound various phylogenetic
approaches (Schierup and Hein 2000; Hedge and Wilson
2014). However, recombination tracts in E. coli are fairly short,
with estimates of average length ranging from 50 to 550 bp
(Touchon et al. 2009; Didelot et al. 2012). As such, large
portions of the genome can in fact share the same phylogeny
(Didelot and Wilson 2015; De Maio and Wilson 2017). Thus,
whether recombination will in fact confound phylogenetically
informed inferences of trait correlations is an open question.
Moreover, nonphylogenetic methods are expected to yield
spurious correlations when the data are phylogenetically
ceftazidime MIC (ug/mL)
Fr
e
qu
en
cy
0.25 0.5 1 2 4 8 16 32 64 128
0
2
4
6
8
A
ciprofloxacin MIC (ng/mL)
15.6 62.5 250 1000 4000 16000
0
5
10
15
B
meropenem MIC (ug/mL)
C
0.25 0.5 1 2
0
2
4
6
8
10
12
14
Growth rate in TSB (OD600/min)
Fr
e
qu
en
cy
0.02 0.04 0.06 0.08
0
2
4
6
8
10
12
D
Growth rate in LB (OD600/min)
0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09
0
2
4
6
8
10
E
Growth rate in M9 (OD600/min)
0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07
0
2
4
6
8
10
12
F
FIG. 1.—Variation in phenotypic traits among 39 clinical isolates of Escherichia coli. Substantial variation is evident for resistance to ceftazidime (A; CLSI
resistance breakpoint: 16lg/ml) and ciprofloxacin (B; CLSI resistance breakpoint: 4lg/ml), but not for meropenem (C; CLSI resistance breakpoint: 4lg/ml).
Growth rates in TSB (D), LB (E), and M9 minimal mediumþglucose (F) also show wide variation.
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structured (Felsenstein 1985). Among the clinical strains stud-
ied here, negative correlations between growth rate and drug
resistance are suggested by both phylogenetic and nonphy-
logenetic methods, albeit weakly in the latter case. We inter-
pret this broad consistency between approaches as
compelling evidence for a trade-off between resistance and
fitness in the absence of drug.
Genetic Basis of Resistance
The most parsimonious explanation for a trade-off between
resistance and growth rates is that resistance determinants
are themselves costly. The major determinants of resistance
to fluoroquinolones and to cephalosporins are well docu-
mented. High-level fluoroquinolone resistance is typically con-
ferred by chromosomal mutations in genes encoding the
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FIG. 2.—Correlations between growth rates and drug resistance. Growth rates were measured in two rich media, TSB (A and B) and LB (C andD), and in
M9 minimal mediaþglucose (E and F). MIC assays were used to measure resistance toward ceftazidime (A, C, and E) and ciprofloxacin (B, D, and F). Linear
regression (solid line) of growth rate on log2(MIC) was used to assess the relationship between resistance and growth rate for each medium/antibiotic pair.
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topoisomerases targeted by these drugs, with gyrA and gyrB
encoding the subunits of DNA gyrase, and parC and parE
encoding the subunits of Topoisomerase IV. Resistance can
also be conferred by mutations affecting efflux and mem-
brane permeability, typically in the transcriptional regulator
marR or in the porin-encoding genes ompF and ompC
(reviewed in Redgrave et al. 2014). ESBL-activity, by contrast,
is conferred by plasmid-borne extended spectrum b-lacta-
mases, with the CTX-M-14 and CTX-M-15 ESBL variants
most prevalent (Canton et al. 2012).
We sequenced the genomes of all 39 clinical isolates to
identify determinants of fluoroquinolone- and b-lactam-resis-
tance. De novo assemblies were used for the detection of
accessory genome elements, such as plasmids, that contribute
to resistance. The average length of the de novo assemblies
was 5.1 Mb, with an average coverage of 35. Average N50,
the size of the contig such that 50% of the genome assembly
is contained in contigs of this length or larger (Lin et al. 2011),
was 2,910,985 bp (supplementary table S1, Supplementary
Material online). Chromosomal point mutations were called
from reference-based assemblies using E. coli K-12 (MG1655)
as a reference.
We found a wide range of known fluoroquinolone- and b-
lactam-resistanceelements in thegenomesofthesestrains.Four
groups of b-lactamase producing genes were identified using
ResFinder (fig. 4 and supplementary table S1, Supplementary
Material online): TEM (-1B, -1C, 116-like), OXA (-1 and 36-like),
CTX-M (-14 and -15) and SHV (-2 and -12). Most of the
ESBL-positive strains sequenced here carry CTX-M genes. The
same strains harbor IncF-plasmids (supplementary table S1,
SupplementaryMaterialonline), consistentwithpreviousfind-
ings that CTX-M-14 and -15 are harbored on IncF plasmids
(Carattoli 2009; Li et al. 2015). However, CTX-M genes were
not found in three ESBL-positive isolates (pb27, pb31 and
pb38), suggesting that the OXA and/or SHV b-lactamases
carried by these strains are responsible for their resistance
to cephalosporins. Plasmid carriage could well contribute
to fitness reductions associated with ceftazidime resis-
tance, as plasmid carriage often—although not always—
confers a cost (reviewed in Vogwill and MacLean 2015;
Wong 2017).
Among the CipR isolates sequenced here, the majority
carry known resistance mutations in the quinolone
resistance-determining region (QRDR) of the gyrA gene. Out
of 24 strains classified as CipR according to CLSI breakpoints
(Clinical and Laboratory Standards Institute 2018), 16 carry
two canonical QRDR mutations, S83L and D87N, and a
17th carries only the S83L mutation. All 17 of these strains
also carry one or two mutations in the QRDR of parC (S80I
and/or E84G and/or E84V). The fitness effects of fluoroquin-
olone resistance mutations have been measured in a variety of
bacteria; most, but not all, target mutations are costly (Bagel
et al. 1999; Kugelberg et al. 2005; Balsalobre and de la
Campa 2008), and in some cases costs are dependent on
genetic background (Luo et al. 2005).
Plasmid-mediated quinolone resistance determinants were
also identified in our sample. Eight isolates carry predicted
aac(60)Ib-cr genes; this aminoglycoside-acetyltransferase vari-
ant has been shown to inactive fluoroquinolones by acetyla-
tion (Robicsek et al. 2006). Six of these aac(60)Ib-cr-bearing
strains also carry chromosomal resistance mutations, whereas
two do not. Finally, 5 isolates (pb12, pb14, pb19, pb28, and
pb34) carry neither gyrA nor parC mutations, nor aac(60)Ib-cr
genes.marRmutations are also absent from these strains, and
no plasmid-borne quinolone resistance (qnr) genes (Martınez-
martınez et al. 1998) were predicted for these strains. These
results suggest the presence of other, previously uncharacter-
ized, resistance determinants.
Environmentally Variable Compensatory Evolution
At first blush, the available data suggest that costs associated
with fluoroquinolone-resistance mutations, as well as with
plasmid carriage, may well underlie fitness trade-offs associ-
ated with antibiotic resistance (figs. 2 and 3). Nonetheless,
many studies have shown that the costs associated with
Table 1
Effects of Growth Environment and Drug Resistance on Growth Rates, As
Estimated by Linear Regression
Factor Estimate (SE) T P Value
Cip MIC 7.4104 (3.6104) 2.04 0.044
Cef MIC 9.8104 (5.5104) 1.80 0.075
Environment: min 0.037 (0.004) 9.28 1.55310215
Environment: TSB 0.003 (0.004) 0.65 0.518
NOTE.—Interaction terms were nonsigniﬁcant in all cases (i.e., costs of resistance
were similar across environments) and were dropped. Antibiotic resistance effects
were included in the model as log2-transformed MIC values. Bold indicates signiﬁ-
cance at P < 0.05.
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FIG. 3.—Phylogenetically controlled correlations between growth
rates and drug resistance in three media (TSB, LB, M9 minimal medium-
þglucose) for two antibiotics (ciprofloxacin, ceftazidime). For each me-
dium—drug pairing, the median estimate of the correlation coefficient is
given, with 95% credible intervals. The Bayes Factor (BF) gives confidence
in the correlation.
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resistance mutations can be easily and rapidly ameliorated via
serial passage in antibiotic-free medium (Andersson 2006;
Andersson and Hughes 2010; Wong 2017). Such compensa-
tory evolution occurs in as little as a few dozen generations,
and frequently leaves resistance intact. In the context of the
current study, the apparent frequency and ease of compen-
satory evolution is problematic: if compensatory evolution
were to occur so readily in clinical populations, then we would
not expect to observe negative correlations between resis-
tance and growth rates. In other words, why have the costs
of resistance not been erased by compensatory evolution?
One possible answer to this question is that compensatory
evolution may be environment specific (MacLean and Vogwill
2014): mutations conferring fitness benefits to the resistant
mutant in one environment may be neutral or deleterious in
other environments. As such, even if compensatory mutations
have occurred in some clinically relevant setting (e.g., the
blood stream or urinary tract), those mutations may not con-
fer a benefit in other locales (e.g., the TSB, LB, and minimal
medium used in this study). Previous findings on this topic are
mixed: a few experiments suggest that mutations that are
compensatory in one environment are also compensatory in
other environments (Bjorkman et al. 2000; Nagaev et al.
2001). For example, fusidic acid resistance mutations in the
EF-G gene in S. aureus are costly in both laboratory medium
and in a rat model of infection, whereas compensatory
mutations evolved in the lab were also compensatory in
rats. Interestingly, the reverse was also true: the most com-
mon compensatory mutation in rats, EF-G A67V, was also
compensatory in the lab. The generality of this result remains
unclear, however, as another common rat-compensatory mu-
tation, EF-G V475L, did not provide a fitness increase in lab-
oratory medium (Nagaev et al. 2001).
In order to further test the environmental specificity of
compensatory mutations, we evolved replicate populations
of two CipR mutants of E. coli, gyrA D87G and marR R94C,
in drug-free LB for 100 generations. Both genotypes initially
suffered a cost in the absence of drug, with relative fitness
estimates of 0.73 (SE: 0.035) and 0.88 (SE: 0.062), respec-
tively. Following compensatory evolution, competitive fitness
assays were carried out on a single clone isolated from each
population. Substantial fitness gains were observed for pop-
ulations evolved from the gyrA D87G ancestor (fig. 5A; one-
tailed t-test P¼ 3.1 109). Fitness increases in the marR
R94C mutant were more modest, with a nonsignificant aver-
age increase in fitness (P¼ 0.17). When fitness was measured
in TSB, another rich medium, significant increases in fitness
were observed for genotypes evolved from both gyrA
D87G (P¼ 0.009) and marR R94C (P¼ 0.013). This in-
crease in fitness is perhaps not surprising, given that
both LB and TSB are rich media, and so the same muta-
tions might confer an advantage under both conditions. In
FIG. 4.—Phylogeny and drug resistance mechanisms for the sequenced clinical isolates. Presence/absence of gyrase mutations and beta-lactamases are
given on the right-hand side of the figure. Strain names are color-coded according to their resistance profile (CipR or CipS, and ESBL-negative or positive).
Basra et al. GBE
674 Genome Biol. Evol. 10(2):667–679 doi:10.1093/gbe/evy030 Advance Access publication February 7, 2018
Downloaded from https://academic.oup.com/gbe/article-abstract/10/2/667/4843993
by Carleton University Library user
on 05 April 2018
minimal mediumþ glucose, neither initial resistance mu-
tation conferred a cost, with relative fitness estimates of
0.91 (SE: 0.08) and 1.02 (SE: 0.04). Genotypes that
evolved in LB did not increase fitness in minimal medium
for populations derived from either ancestor (fig. 6C;
P¼ 0.19 and P¼ 0.98, respectively), but this may simply
reflect the absence of initial fitness costs.
Overall, responses to selection (i.e., the change in fitness
over the course of the selection experiment) were uncorre-
lated between TSB and LB, or between M9 minimal medium
and LB (fig. 6). That is, the magnitude of the fitness gain in LB
did not predict fitness changes in either alternative
environment. This is true even in TSB (fig. 6A)—although
fitness increased overall in TSB, the sizes of the fitness
increases were uncorrelated. Correspondingly, ANOVA indi-
cates significant effects of genotype, environment, and
genotype  environment interactions on the response to
selection (table 2).
We therefore propose that compensatory evolution may
be limited by environmental context—whereas fitness gains
may be achieved in specific settings, those improvements may
be inconsistent in alternative environments (fig. 6). By con-
trast, the fitness costs imposed by resistance mutations do
appear to be fairly (although not entirely) consistent across
environments (MacLean and Vogwill 2014). Thus, we expect
that resistance will sometimes trade off with fitness, even in
the face of compensatory evolution.
Implications for the Control of AMR
Restriction protocols, whereby a drug or drug class is withheld
in hopes of reducing the prevalence of resistance, have been
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FIG. 5.—Direct and indirect responses to selection in the absence of antibiotic. Ancestral fitness is given by the black bar, and mean (6SE) fitness for 12
evolved populations is given in gray. Compensatory evolution in LB resulted in a significant increase in fitness in LB for gyrA D87G-derived populations (A),
and for populations derived from both mutant ancestors in TSB (B). No increase in fitness was observed in M9 minimal mediumþglucose (C), although
neither resistance mutation imposed a significant decrease in fitness.
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moderately successful in both human and animal populations
(Enne 2010). For example, ciprofloxacin resistance in E. coli
dropped from 12–14% to 9% following restricted use of
quinolones in Israel over a 7-month period (Gottesman
et al. 2009). Similarly, wholesale restriction of veterinary anti-
biotic use in the Netherlands has been accompanied by wide-
spread reductions in AMR in animal isolates (Speksnijder et al.
2015). The success of restriction protocols is broadly consis-
tent with the assumption that AMR is costly; our data indicate
that this assumption is largely well founded, with a negative
association between resistance and growth rates in both
phylogeny-independent (fig. 2 and table 1) and phylogenet-
ically controlled (fig. 3) analyses.
There are nonetheless important exceptions to the success
of restriction protocols, wherein drug limitation has not been
followed by a drop in the prevalence of resistance. Restriction
of clinical trimethoprim use in Sweden (Sundqvist et al. 2010),
and of sulphonamide use in the United Kingdom (Enne et al.
2001), failed to reduce the prevalence of resistance to these
two drugs. Furthermore, reduction of veterinary antibiotic use
in the Netherlands has had no effect on the prevalence of the
zoonotic pathogen MRSA ST398 (Dierikx et al. 2016), even
though other AMR strains have dropped in frequency. There
are a number of possible explanations for these failures of
drug restriction, including coselection (whereby AMR ele-
ments are linked), the existence of AMR genotypes that do
not suffer a cost, and the influence of genetic background
(Melnyk et al. 2014; Vogwill and MacLean 2015; Wong
2017).
Our findings suggest a role for genetic background in mit-
igating the costs of resistance. This is most clear in the case of
quinolone resistance. Most of the CipR strains studied here
carry the same gyrA S83L D87N haplotype, but the growth
rates of these strains in TSB vary by >4-fold (supplementary
table S1, Supplementary Material online). This variation in
growth rates among strains bearing the same resistance allele
may be due to epistasis, whereby the costs of resistance are
dependent on genetic background. Alternatively, the varia-
tion in growth rates may be independent of resistance, such
that CipS derivatives of these strains would show similar differ-
ences in growth rates. In either case, however, there are
highly CipR genotypes that show similar growth rates to
CipS genotypes. Assuming that growth rate is a reasonable
proxy for fitness, these CipR genotypes would therefore be
expected to persist in the absence of drug.
Natural Variation and Tradeoffs
Microbial studies of tradeoffs have largely focused on the
effects of single mutations, such as AMR mutations (reviewed
in Melnyk et al. 2014; Vogwill and MacLean 2015), or on
experimentally evolved populations differing by a handful of
mutations (Bohannan et al. 2002; Schick et al. 2015). In such
studies, fitness tradeoffs can be attributed to specific muta-
tions, guaranteeing that tradeoffs are in fact due to antago-
nistic pleiotropy rather than the presence of linked mutations
that are deleterious in some environments but not others.
Moreover, knowledge of the specific mutations underlying
tradeoffs allows for greater mechanistic understanding.
There are nonetheless compelling reasons to adopt the
complementary approach, that of measuring trait correlations
among natural microbial isolates. Importantly, the fitness
−0.2 0.0 0.2 0.4
−
0.
10
0.
00
0.
10
0.
20
LB
TS
B
A
−0.2 0.0 0.2 0.4
−
0.
2
−
0.
1
0.
0
0.
1
LB
M
9
B
FIG. 6.—No correlation between direct and indirect responses to selection. Response to selection was measured as the difference in fitness between the
ancestral and evolved genotypes, for genotypes derived from gyrA D87G (gray) or marR R77H (black). Correlations were nonsignificant between LB and TSB
(A), and between LB and M9 minimal mediumþglucose (B).
Table 2
Effects of Genotype and Environment on the Response to Selection
Factor F P Value
Genotype 21.05 2.33105
Environment 26.56 5.46109
Genotypeenvironment 8.92 4.1104
NOTE.—Populations were evolved in drug-free LB for 100 generations, and ﬁt-
ness was measured in LB, TSB, and minimal medium.
Basra et al. GBE
676 Genome Biol. Evol. 10(2):667–679 doi:10.1093/gbe/evy030 Advance Access publication February 7, 2018
Downloaded from https://academic.oup.com/gbe/article-abstract/10/2/667/4843993
by Carleton University Library user
on 05 April 2018
effect of a mutation can vary depending on genetic back-
ground (Wong 2017)—a given mutation may be beneficial,
neutral, or deleterious, depending on the presence of other
mutations in the genome. Laboratory studies of trade-offs
tend to be restricted to a single genetic background, which
potentially limits the generalizability of their findings. Thus, by
using natural variation to detect tradeoffs, we can take the
effects of genetic background into account.
Although widespread in multicellular organisms, natural
variation-based studies of trade-offs are relatively rare in
microbes (reviewed in Ferenci 2016). Nonetheless, it is clear
that trade-offs are widespread, and that they contribute to
ecological specialization and to the maintenance of diversity.
For example, Clark et al. (2015) measured a range of pheno-
typic traits among Pseudomonas aeruginosa isolates from an
adult with cystic fibrosis (Clark et al. 2015). They found neg-
ative correlations between traits involved in virulence, and
those involved in chronic infection, indicative of a trade-off
between long-term survival and virulence (see also
Workentine et al. 2013). Similarly, Phan et al. identified a
trade-off between survival and nutritional competence, likely
mediated by membrane permeability (Phan and Ferenci
2013).
Our finding of a negative relationship between growth
rates and drug resistance (figs. 2 and 3; table 1) similarly
suggests that E. coli must trade-off between growth and sur-
vival. However, this trade-off is not absolute, since no rela-
tionship between resistance and growth was observed in
minimal media. The mechanistic underpinning of this relation-
ship is unclear, although it may reflect slower growth in min-
imal medium; slow growth may be accompanied by reduced
metabolic demands and a greater tolerance for reduced
enzymatic function. More broadly, we highlight the impor-
tance of measuring a wide range of traits, in order to gain
a more complete appreciation of the various trade-offs (or
lack thereof) that may contribute to the maintenance of
diversity.
Given the ease of bacterial genome sequencing, and the
relative ease of phenotypic measurement in bacteria, there is
much promise in using bacterial systems to measure, quantify,
and understand trade-offs. Such efforts may in turn help to
understand the considerable diversity of bacteria.
Supplementary Material
Supplementary data are available at Genome Biology and
Evolution online.
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